Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
In October 2024, we explored the untapped potential of psychedelic stocks in mental health treatment, laying out the case for a sector that was just beginning to mature. Eighteen months later, the landscape has been reshaped by a devastating FDA rejection, a wave of corporate consolidation, and a series of clinical breakthroughs that have quietly repositioned the survivors as some of the most asymmetric opportunities in biotech.
The headlines told one story. The data tells another.
The MDMA Rejection That Changed Everything
In August 2024, just weeks before our original analysis went live, the FDA declined to approve Lykos Therapeutics’ MDMA-assisted therapy for PTSD. The advisory committee had voted 10-1 against approval, citing concerns about trial design, functional unblinding, and ethical misconduct at one clinical site. For an industry that had pinned enormous hope on MDMA as the first psychedelic to cross the regulatory finish line, the decision landed like a depth charge.
[Also See: Untapped Potential of Psychedelic Stocks in Mental Health Treatment]
By September 2025, the FDA publicly released its Complete Response Letter, making the agency’s reasoning transparent for the first time. MAPS, the nonprofit that had championed MDMA research for over three decades, accused the FDA of moving the goalposts after years of collaborative protocol design. Whether you view the rejection as principled regulatory caution or bureaucratic overreach, the practical effect was the same: the poster child of psychedelic medicine became a cautionary tale, and retail investor sentiment cratered across the entire sector.
Here is where the contrarian lens becomes essential. The MDMA rejection did not invalidate the science behind psychedelic therapy. It exposed the unique regulatory complexity of combining a psychoactive drug with psychotherapy in a single approval package. The companies that learned from this lesson, and adapted their trial designs accordingly, are now sitting on some of the strongest clinical datasets in psychiatry.
Compass Pathways: First Psychedelic to Clear Phase 3
The most significant development since our original article, and arguably the most important milestone in the history of psychedelic medicine, belongs to Compass Pathways (NASDAQ: CMPS). In June 2025, Compass became the first company to report positive Phase 3 efficacy data for a classic psychedelic when its COMP005 trial showed that a single 25mg dose of COMP360, a synthetic psilocybin formulation, produced a highly statistically significant reduction in depression severity at six weeks compared to placebo.
Then in February 2026, Compass did it again. The second Phase 3 trial, COMP006, also hit its primary endpoint with high statistical significance. Two doses of COMP360 25mg, administered three weeks apart, showed effects emerging as early as the day after dosing and lasting through at least 26 weeks. The independent safety board found no unexpected safety signals across either trial.
What makes these results particularly striking is the patient population. Treatment-resistant depression is notoriously difficult to move the needle on. Of the roughly four million TRD patients in the United States, fewer than 200,000 currently receive an FDA-approved treatment for the condition. The unmet need is vast, and the competitive landscape is thin.
Compass is now preparing to meet with the FDA to confirm a rolling NDA submission strategy, with the final dataset expected in early Q3 2026 and submission targeted for Q4. The company has raised $350 million through financing and warrants, extending its cash runway into 2028, and is building out commercial infrastructure to be launch-ready by the end of this year. If all goes to plan, COMP360 could become the first classic psychedelic approved by the FDA, potentially reaching the market in 2027.
MindMed: The LSD Play With Three Phase 3 Trials Running
MindMed (NASDAQ: MNMD) has quietly assembled the broadest Phase 3 pipeline in the psychedelic sector. The company is running three simultaneous pivotal trials of MM120, a pharmaceutically optimised form of LSD, targeting both generalised anxiety disorder and major depressive disorder.
The Voyage study, launched in late 2024, was the first-ever Phase 3 trial of LSD for any condition. The Panorama study, initiated in January 2025, expanded the program to European sites and added a 50-microgram control arm to address the functional unblinding concerns that sank the MDMA approval. And in April 2025, MindMed dosed the first patient in Emerge, its Phase 3 study in MDD.
The Phase 2b data underpinning this expansion was published in the Journal of the American Medical Association (JAMA) in late 2025, demonstrating a dose-dependent reduction in anxiety from a single treatment with a 65% clinical response rate and 48% remission rate sustained through 12 weeks. Publication in JAMA is significant. It signals that the medical establishment is taking LSD-based therapy seriously as a pharmacological intervention, not merely a curiosity.
Topline data from Voyage is expected in the first half of 2026, with Panorama and Emerge readouts following later in the year. MindMed raised $258.9 million in October 2025, giving it the financial runway to see all three programs through their critical readouts. The company has described 2026 as the most significant year in its history. If even one of these trials hits, MindMed will have a clear path toward FDA submission. If two or three succeed, the company’s current market capitalisation around $700 million may look remarkably cheap in retrospect.
AtaiBeckley: The Merger, the Breakthrough, and the 90-Minute Treatment
One of the more consequential moves in the sector was the strategic merger of atai Life Sciences and Beckley Psytech, completed in November 2025 to form AtaiBeckley (NASDAQ: ATAI). The deal was triggered by positive Phase 2b results for BPL-003, an intranasal formulation of 5-MeO-DMT that delivered rapid antidepressant effects with a psychedelic experience lasting roughly 90 minutes, far shorter than the six to eight hours typical of psilocybin or LSD sessions.
The clinical profile of BPL-003 is notable for its practical implications. The majority of patients met readiness-for-discharge criteria at the 90-minute post-dose assessment, making the treatment model compatible with existing interventional psychiatry workflows like those already established for esketamine (Spravato). In the open-label extension study, patients who received two doses eight weeks apart showed a 63% response rate and 48% remission rate at 16 weeks.
The FDA granted Breakthrough Therapy Designation to BPL-003 in October 2025, and in March 2026 AtaiBeckley announced a successful End-of-Phase-2 meeting with the FDA, confirming support for two parallel Phase 3 trials, ReConnection 1 and ReConnection 2, expected to begin mid-2026. The company also continues advancing VLS-01 (a DMT buccal film) for TRD and EMP-01 (R-MDMA) for social anxiety disorder, both in Phase 2.
Cybin: The Deuterated Psilocybin Dark Horse
Cybin (NYSE: CYBN) has taken a differentiated approach with CYB003, a deuterated psilocybin analogue designed for shorter treatment sessions and more predictable dosing. Their Phase 2 data showed a 75% remission rate in the 16mg dose group after two doses, which is an exceptional number for any depression study.
The company launched its Phase 3 PARADIGM program in late 2024, with the first pivotal study (APPROACH) dosing underway across US and European sites and topline results expected in Q4 2026. A second pivotal study, EMBRACE, received approvals from regulators in the UK, Europe, and Australia throughout 2025. Critically, CYB003 is being studied as an adjunctive treatment, meaning patients can stay on their existing antidepressants rather than tapering off. This design choice directly addresses one of the practical barriers that has made psilocybin therapy intimidating for both patients and prescribers.
The Consolidation Nobody Is Talking About
Since our original article, the psychedelic sector has undergone a brutal Darwinian culling. Many of the smaller companies we profiled, including Small Pharma, Field Trip Health, Numinus Wellness, and Revitalist Lifestyle, have either been acquired for pennies, delisted, or ceased meaningful operations. The speculative fringe of the sector has been almost entirely wiped out.
What remains is a concentrated group of well-funded, late-stage companies with FDA Breakthrough Therapy Designations, published data in top-tier journals, and hundreds of millions in cash on hand. This is the classic pattern that precedes biotech sector re-ratings: the weak hands get shaken out, the survivors consolidate, and the market eventually reprices the assets based on clinical and commercial reality rather than hype-cycle sentiment.
The AdvisorShares Psychedelics ETF (NYSE: PSIL) offers diversified exposure for investors who prefer not to pick individual winners, though the concentrated nature of the sector means the top three or four holdings drive most of the performance.
The Contrarian Case
Here is what the consensus is missing. The MDMA rejection taught the sector how to run trials that will survive FDA scrutiny. Compass has now delivered two positive Phase 3 studies, a feat that most biotech companies never achieve once. MindMed’s JAMA publication legitimised LSD-based therapy in the eyes of the medical establishment. AtaiBeckley’s 90-minute treatment model could make psychedelic therapy as scalable as a Spravato session.
The psychedelic drugs market is projected to grow at 12.1% annually through 2030 according to Grand View Research, and the treatment-resistant depression market alone represents millions of patients who have exhausted conventional options. Yet the leading companies in this space still trade at market capitalisations that would be considered modest for a single-asset biotech, let alone platforms with multiple Phase 3 programs.
The risk has not disappeared. Clinical trial failure, regulatory delays, reimbursement uncertainty, and the political sensitivity of psychedelic compounds remain real headwinds. But the risk-reward calculus has shifted dramatically since October 2024. The question is no longer whether psychedelic therapy works. The Phase 3 data has answered that. The question is whether investors will recognise the shift before the NDA submissions make it obvious to everyone.
For those who built positions during the post-MDMA sentiment washout, 2026 and 2027 could deliver the kind of catalysts that turn a contrarian thesis into a consensus one. And as any experienced investor knows, that transition is where the real returns are made.
